Cancer Systems Biology Consortium

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Cancer is a complex disease system involving multiple molecular, genetic, and cellular events. From its early initiation through progression and metastasis, cancer can adapt and evolve as a result of both internal and external signals. These properties make cancer difficult to predict, prevent, and treat. There has been significant progress in characterizing the genetics of cancer, as well as the downstream effects on the molecular and cellular pathways that are critical for the initiation and progression of cancer. However, studies focused on the role of one gene have highlighted the need to understand cancers as integrated systems of genes, networks, and intercellular interactions.

Cancer systems biology is uniquely poised to address the complexity associated with cancer through its unique integration of experimental biology and computational and mathematical analysis. Instead of viewing cancer through the lens of a single mutation or alteration, the goal of cancer systems biology is to provide a birds eye view of the changing cancer ecosystem, thus allowing cancer biologists and oncologists to understand and predict how one alteration effects an entire tumor system. The multidisciplinary Cancer Systems Biology Consortium, which includes cancer biologists, engineers, mathematicians, physicists, and oncologists, aim to tackle the most perplexing issues in cancer to increase our understanding of tumor biology, treatment options, and patient outcome.

The Impact of Cancer Systems Biology on Cancer Research

There has been an explosion in the quantity of available experimental data from high-throughput technologies, such as genomic sequencing, transcriptomics, metabolomics, and proteomics. Additionally, targeted experiments on a smaller scale have provided important information about complex interactions within and between cells. Systems analyses and predictive modeling are necessary to integrate across these datasets that span different length and time scales to convert them into knowledge. For ten years from 2004-2014, DCB supported the Integrative Cancer Biology Program (ICBP), a precursor to the current Cancer Systems Biology Consortium. The ICBP brought together cancer biologists and oncologists with computer scientists, mathematicians, and engineers to tackle important cancer questions including the identification of tumor master transcriptional regulators, the role of microRNAs in cancer progression and metastasis, the development of drug resistance in heterogeneous tumor contexts, and optimization of combination therapies for cancer treatment. It is envisioned that the past successes of cancer systems biology will encourage investigators to bring these tools to bear on emerging and difficult cancer questions that will require a systems approach to fully comprehend.

Funding Opportunities

The Cancer Systems Biology Consortium consists of specialized U01 Research Projects, U54 CSBC Research Centers, and a U24 Coordinating Center. Ongoing funding announcements for the CSBC components can be found at the following links:

  • Emerging Areas in Cancer Systems Biology (U01 Research Projects): PAR-16-131
  • Research Centers for the Cancer Systems Biology Consortium: RFA-CA-15-014

Currently Funded Projects (as of September 2017)

Research Centers awarded grants in the first round of RFA-CA-15-014 include:

Institution Principal Investigators Center Title
Columbia University Dr. Andrea Califano and Dr. Barry Honig Center for Cancer Systems Therapeutics (CaST)
Memorial Sloan Kettering Cancer Center Dr. Christina Leslie and Dr. Alexander Rudensky The CSBC Research Center for Cancer Systems Immunology at MSKCC
Stanford University Dr. Sylvia Plevritis and Dr. Garry Nolan Modeling the role of lymph node metastases in tumor-mediated immune suppression
Yale University Dr. Andre Levchenko Systems Analysis of Phenotypic Switch in Control of Cancer Invasion

 Research Centers awarded grants in the second round of RFA-CA-15-014 include:

Institution Principal Investigators Center Title
Massachusetts Institute of Technology Dr. Scott Manalis and Dr. Doug Lauffenburger Quantitative and Functional Characterization of Therapeutic Resistance in Cancer
Oregon Health & Science University Dr. Joe Gray, Dr. Adam Margolin, Dr. Rosalie Sears, and Dr. Claire Tomlin Measuring, Modeling and Controlling Heterogeneity
University of California, San Francisco Dr. Nevan Krogan and Dr. Trey Ideker Research Center for Cancer Systems Biology: Cancer Cell Map Initiative
University of Texas Health Science Center Dr. Tim Huang, Dr. Victor Jin and Dr. Qianben Wang Systems Analysis of Epigenomic Architecture in Cancer Progression
University of Utah Dr. Andrea Bild Combating Subclonal Evolution of Resistant Cancer Phenotypes

Research Projects awarded grants under PAR-16-131 include:

Institution Principal Investigator Center Title
Georgia Institute of Technology Dr. Melissa Kemp, Dr. David Boothman, and Dr. Cristina Furdui Model-Based Prediction of Redox-Modulated Responses to Cancer Treatments
Massachusetts Institute of Technology Dr. Doug Lauffenburger, Dr. Wilhelm Haas and Dr. Kevin Haigis Systems Approaches to Understanding the Relationships Between Genotype, Signaling, and Therapeutic Efficacy
Mayo Clinic Arizona Dr. Kristin Swanson, Dr. Leland Hu, Dr. Joseph Mitchell, and Dr. Nhan Tran Quantifying Multiscale Competitive Landscapes of Clonal Diversity in Glioblastoma
University of California, Los Angeles Dr. Aaron Meyer, Dr. Eric Haura, and Dr. Forest White Precision Lung Cancer Therapy Design through Multiplexed Adapter Measurement
University of Virginia Dr. Kevin Janes An Integrated Systems Approach for Incompletely Penetrant Onco-Phenotypes
Vanderbilt University Dr. Vito Quaranta and Dr. Carlos Lopez Phenotype Transitions in Small Cell Lung Cancer

The Coordinating Center awarded for RFA-CA-15-015, which will contribute to the research missions of the Cancer Systems Biology Consortium and the Physical Sciences-Oncology Network is:

Institution Principal Investigator Center Title
Sage Bionetworks Dr. Justin Guinney Coordination Center for Open Collaboration in Systems Biology

Additional Information about the Consortium can be found on the CSBC page maintained by the Coordinating Center.

Several U01 Research Projects that were previously associated with the Integrative Cancer Biology Program were the initial members of the CSBC. These projects include those funded under the Bridging the Gap Between Cancer Mechanism and Population Science and the Collaborative Research in Integrative Cancer Biology U01 programs (no receipt dates remain for these programs).

Pre-application Webinar Materials

Slides for PAR-16-131

The National Cancer Institute (NCI) held a public pre-application webinar on Friday, October 13, 2017 for the Funding Opportunity Announcement (FOA) PAR-16-131 entitled “Emerging Questions in Cancer Systems Biology (U01)”. NCI staff members involved in managing this program provided technical assistance to potential applicants by explaining the goals and objectives of the Cancer Systems Biology Consortium (CSBC) initiative and answered questions from attendees about the CSBC U01 Research Projects.

Slides from the webinar held on 10/13/2017 are now available:

  • Posted: August 29, 2016

Most text on the National Cancer Institute website may be reproduced or reused freely. The National Cancer Institute should be credited as the source and a link to this page included, e.g., “Cancer Systems Biology Consortium was originally published by the National Cancer Institute.”

Please note that blog posts that are written by individuals from outside the government may be owned by the writer, and graphics may be owned by their creator. In such cases, it is necessary to contact the writer, artists, or publisher to obtain permission for reuse.

We welcome your comments on this post. All comments must follow our comment policy.